United Therapeutics (UTHR)
(Delayed Data from NSDQ)
$276.26 USD
+1.13 (0.41%)
Updated Jun 3, 2024 04:00 PM ET
After-Market: $276.13 -0.13 (-0.05%) 4:58 PM ET
3-Hold of 5 3
B Value A Growth A Momentum A VGM
Brokerage Reports
United Therapeutics Corporation [UTHR]
Reports for Purchase
Showing records 581 - 590 ( 590 total )
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Tyvaso Accelerates Top-Line Growth.
Provider: AURIGA USA
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q1 Financials Beat: Tyvaso Strength Was Understandable But Is Remodulin?s Q1 Strength Sustainable?
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q1 Preview: We Think Q1 Will Be Either In-Line Or Squeak By Consensus--Tyvaso Is The Wild Card.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Tyvaso Uptake Looks Strong - Reiterate Buy.
Provider: AURIGA USA
Company: United Therapeutics Corporation
Industry: Medical - Drugs
In Response To The Tyvaso MAA Withdrawal, We Are Lowering Our Fair Value to $59 But Maintaining Our NEUTRAL Rating.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Robust Quarter - Reiterating Buy
Provider: AURIGA USA
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q4 Revenues Slightly Beat Our and Consensus Estimates but GAAP EPS Missed on Higher Operating Expenses
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Although We Raised Our Q4 Estimates, Consensus Is Still Relatively High. Even So, We Believe Investors Are Focused On Better Than Expected Product Launches
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L